CHILDRENS CANCER GROUP

匹兹堡儿童癌症组织(CCG)的主要目标是 以改善患有癌症的儿童的预后。这个目标是 通过以下方式实现： 1.为患有癌症的儿童提供受益的机会 参与CCG协议。 2.为患者提供CCG研究方案。 3.为这些研究提供患者的生物标本 协议。 4.为结果分析提供准确的患者数据。 5.提供熟练的医疗专业人员来规划、实施和评估 这些研究。 6.与当地研究项目一起开发和测试新想法。 7.以最低的效率管理和开展这些研究 成本。 这项研究是在匹兹堡儿童医院进行的， 一家235个床位的非营利性医院，这是儿科转诊中心 对于四百万到五百万人口来说。生防护中心与 匹兹堡大学医学院，并担任其系 儿科医生。卫生防护中心也是匹兹堡癌症协会的正式成员。 研究所是美国国立卫生研究院指定的综合性癌症中心，一直是 自1961年起担任CCG成员。在过去的一年里，一个完全翻新的， 肿瘤专科病房和CCG批准的新骨髓移植 (BMT)计划已经开通，以提高我们进行研究的能力。 我们的多学科儿科肿瘤学/骨髓移植团队已扩大到10个 肿瘤学家，包括外科医生(包括神经科和骨科)， 放射肿瘤学家、诊断放射科医生、儿科病理学家、 血液病理学家，细胞遗传学家，神经学家，流行病学家， 心脏病专家、心理学家和完整的支持团队(护理、数据 管理人员、社会服务、样本协调员等)。在开场的时候 新的共和人民党仰光研究大楼和建立三个新的 教职员工通过独立资助，我们增加了实验室 研究并预计基础研究的贡献将增加 CCG。随着调查人员的增加，我们还预计最多 参与CCG。我们预计将增加患者登记人数 治疗、生物学和流行病学研究。有139名患者 1992年开始研究(治疗、特殊和流行病学)和 我们预计在接下来的几年里学习人数会更高，因为我们 在过去的一年里被批准为一期和BMT中心。我们是 还计划在CCG中发挥更大的科学和管理作用 由于我们最近扩充了员工队伍。此外，我们还有当地的 正在进行的独立癌症研究项目，我们希望这些项目将受益 我们的病人和CCG。这些非CCG临床和实验室癌症 项目包括但不限于：核扩散反应 急性白血病细胞向重组生长因子转化；神经母细胞瘤的治疗 去铁胺；阐明介导的信号转导机制 GM-CSF对CD4的影响；原癌基因信号转导的研究 包括反义分子的抗增殖作用。

The major objective of the Childrens Cancer Group (CCG) in Pittsburgh is to improve the outcome for children with cancer. This objective is achieved by: 1. Providing children with cancer the opportunity to benefit from participation in CCG protocols. 2. Providing patients for CCG research protocols. 3. Providing biologic specimens from patients for these research protocols. 4. Providing accurate patient data for analysis of results. 5. Providing skilled medical professionals to plan, conduct, and evaluate the studies. 6. Developing and testing new ideas with local research projects. 7. Administering and conducting these studies efficiently at the lowest cost. This research is conducted at the Children's Hospital of Pittsburgh (CHP), a 235 bed not for profit hospital which is the pediatric referral center for a population of 4 to 5 million people. CHP is associated with the University of Pittsburgh School of Medicine and serves as its Department of Pediatrics. CHP is also a full member of the Pittsburgh Cancer Institute, an NIH designated comprehensive cancer center and has been a member of CCG since 1961. During the Past year, a completely renovated, dedicated oncology ward and a new CCG approved bone marrow transplant (BMT) program have been opened to improve our ability to conduct research. Our multi-disciplinary pediatric oncology/BMT team has expanded to 10 oncologists and includes surgeons (including neuro and orthopedic), radiation oncologists, diagnostic radiologists, pediatric pathologists, a hematopathologist, cytogeneticists, a neurologist, epidemiologists, cardiologists, psychologists, and a complete support team (nursing, data managers, social service, a specimen coordinator, etc.). With the opening of the new CHP Rangos Research Building and the establishment of three new faculty members with independent funding, we have increased our laboratory research and anticipate an increase in basic research contributions to CCG. With a larger number of investigators, we also anticipate maximum participation in CCG. We expect to increase patient enrollment in therapeutic, biologic, and epidemiologic studies. There were 139 patients entered on study during 1992 (therapeutic, special, and epidemiologic) and we anticipate even a higher on-study number m the coming years since we have been approved as a phase I and BMT center in the past year. We are also planning to take a larger scientific and administrative role in CCG with the recent expansion in our staff. In addition, we have local independent cancer research projects in progress that we hope will benefit our patients and CCG. These non-CCG clinical and laboratory cancer projects include but are not limited to: The proliferative response of acute leukemia cells to recombinant growth factor; neuroblastoma treatment with deferoxamine; delineating mechanisms of signal transduction mediated via GM-CSF on CD4; the study of signal transduction by proto-oncogenes including the anti-proliferative effects of anti-sense molecules.